People · Operator
Named in public records as an officer, director or promoter · active 2012–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tarsa Therapeutics, Inc. | — | Biotechnology | Series B | $46.8M | $21.8M | 2012 |
Gregory Lumpkin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Lumpkin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric Bednarski | 1 | 7 |
| Lewis Geffen | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Richard Levy | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
| Matthew Rieke | 1 | 3 |
| Richard Kollender | 1 | 3 |
| Derek Ferguson | 1 | 2 |
| David Brand | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.